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A B S T R A C T
Background: In valve-sparing aortic root replacement (VSARR), how to reproduce Valsalva sinus has been
an issue. In the original David V procedure, they put plication stitches at sinotubular junction level,
although the reeﬁng effect is limited and distal graft remains larger than native. Other modiﬁed
techniques are two-grafts technique and ready-made Valsalva graft. However, the former needs graft–
graft anastomosis andmay not be cost-effective, while in the latter, the shape of sinus is ﬁxed andminor
adjustment is difﬁcult. David V University of Tokyo modiﬁcation (David V-UT) is our original solution to
that, creating pseudosinus with one straight graft by longitudinal size-reduction running sutures above
each pseudosinus. The purpose of the present study is to investigate long-term outcome of David V-UT.
Methods: We analyzed 59 David V-UT patients from February 2004 to February 2013 and long-term
outcomes were investigated by Kaplan–Meier methods. Risk factors for adverse events ‘‘death or
recurrent aortic insufﬁciency (AI) with or without aortic valve reoperation’’ were analyzed by using Cox
proportional hazard models.
Results: Mean age was 33.1  14.5 years, and 38 patients (64%) were male. Marfan syndrome (MFS)
accounts for 47 patients (80%). Only one patient was with bicuspid aortic valve. No in-hospital mortality was
observed. Mean follow-up was 4.9  2.4 years. Estimated survival was 94.0  3.4% at 5 years. Freedoms from
aortic valve reoperation and recurrent AI greater than mild were 95.7  3.0% and 88.9  4.7% at 5 years,
respectively. In Cox proportional hazard analysis, preoperative AI greater than mild and Z score of annular
diameter were signiﬁcant risks for adverse events (p = 0.027 and 0.045, hazard ratio 6.084 and 1.432, 95% C.I.
1.225–30.21 and 1.008–2.035, respectively).
Conclusions: Even in Marfan-characterized population, David V-UT provided satisfactory long-term
outcome, comparable to other VSARR modiﬁcations. It is simple but can freely reproduce trilobed sinus
with one straight graft.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Introduction
Aortic root replacement (ARR) with composite-valved graft has
been a gold-standard operation for patients with annulo-aortic* Corresponding author at: The University of Tokyo, Department of Cardiac
Surgery, 7-3-1 Hongo, Bunkyo, Tokyo 113-8655, Japan. Tel.: +81 3 3815 5411;
fax: +81 3 5800 8728.
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http://dx.doi.org/10.1016/j.jjcc.2015.03.014
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsectasia (AAE) or other related pathologies [1]. Since the early
1990s, valve-sparing aortic root replacements (VSARRs) have been
gradually conducted in selected cases to avoid permanent antic-
oagulation therapy. Remodeling operation, or Yacoub procedure
[2], has the beneﬁt of forming sinuses of Valsalva, possibly
providing better cusp property by decreasing mechanical stress on
the leaﬂet. However, this procedure has brought an issue of
concern, which is the future dilation of remnant Valsalva sinus
tissues and aortic annulus. On the contrary, reimplantationreserved.
Table 1
Patient characteristics.
David V-UT
Number of patients 59
Age (years) 33.114.5
Sex
Male (%) 38 (64)
Marfan syndrome (%) 47 (80)
Height (cm) 17915
Weight (kg) 66.215.4
Body surface area (m2) 1.80 0.24
Diagnosis
AAE (%) 59 (100)
Root diameter (mm) 53.28.3
Annular diameter (mm) 24.92.7
Z scores of root diameter 8.33.0
Z scores of annular diameter 1.21.8
Bicuspid aortic valve (%) 1 (2)
Hypertension (%) 19 (32)
Diabetes mellitus (%) 1 (1.7)
Hyperlipidemia (%) 6 (10)
Smoking history (%) 17 (29)
Cardiovascular family history (%) 16 (27)
Renal dysfunction (%) 1 (1.7)
Dialysis (%) 0 (0.0)
Preoperative creatinine (%) 0.76 0.36
Chronic obstructive pulmonary disease (%) 8 (14)
Mild 8
Moderate 0
Severe 0
Unknown 0
History of cerebrovascular disease (%) 1 (2)
NYHA class
Class 1 (%) 55 (93)
Class 2 4
Class 3 or greater 0
Preoperative coronary angiogram (%) 14 (24)
0VD 14
1VD 0
2VD or more 0
LV function
Good (%) 48 (81)
Medium 11
Bad 0
Preoperative AI
None to trace (%) 32 (54)
Mild 10
Moderate 11
Severe 6
Arrhythmia (%) 3 (5)
AAE: annuloaortic ectasia; NYHA class: New York Heart Association class; VD:
vessel disease; LV: left ventricle; AI: aortic insufﬁciency.
Table 2
Operative details.
David V-UT (n=59)
Previous cardiac surgery (%) 3 (5)
Concomitant surgery
Aortic valve plasty 9
Mitral valve replacement 0
Mitral valve plasty 1
CABG 8
Hemi/partial arch replacement 1
Total arch replacement 0
Operation time (min) 508132
Pump time (min) 31069
Cross-clamp time (min) 24554
CABG: coronary artery bypass grafting.
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annular stabilization, which might be considered of great value
especially in patients with Marfan syndrome (MFS) or other
connective tissue disorders [4,5]. A disadvantage of the original
reimplantation technique, which is known as David I technique,
was the absence of Valsalva sinuses, which is a possible cause of
abnormal leaﬂet stress that would limit the long-term durability of
the native valves. To overcome this vulnerability, some modiﬁca-
tionswere added. TheDavid V technique is the updated reﬁnements
[6], inwhich they use rather larger graft and put plication stitches at
the level of annulus and sinotubular junction to create pseudosinus.
However, in this original David V technique, the reeﬁng effect of
plication stitches at the sinotubular junction is limited and the distal
portion of the graft tends to remain larger than native aorta. This
diameter gap is not ideal especially in connective tissue disorders
with thin and fragile aortic wall [7]. To date, several modiﬁed
procedures have been advocated. The currentmajor two techniques
are two-grafts technique [8] or ready-made Valsalva graft [9],
however, both cannot make trilobed sinus. The former needs graft–
graft anastomosis and may not be cost-effective, while in the latter
technique, the shape of sinus is already ﬁxed and it is difﬁcult to
make minor adjustments. As Oka et al. pointed out, the two major
causes of late failure after valve-sparing surgery are cusp prolapse
and commissural dehiscence [10], indicating that commissural
height should be carefully set on its ideal position.
From this perspective, we previously reported our simple and
original modiﬁcation of David V technique called ‘‘David V
University of Tokyo modiﬁcation’’ (David V-UT), which can create
trilobed sinus like native one with just one straight graft, by
putting longitudinal size-reduction running sutures on each
pseudosinus [11]. In this method, the height of Valsalva sinus is
freely adjustable, providing greater beneﬁt and ﬂexibility on
commissural height set-up. In addition, diameter of distal graft is
easy to size-down by the running sutures and distal anastomosis
would be easier and safer. The purpose of the present study is to
investigate the long-term outcome of David V-UT and to analyze
risk factors for recurrent aortic insufﬁciency (AI).
Materials and methods
Patient population
Since August 1998, VSARRs have been indicated for selected
cases of non-urgent AAE in the University of Tokyo Hospital, and
especially since February 2004 David V-UT has been performed as
standard VSARR procedure. In the current study, we analyzed
59 successive David V-UT patients from February 2004 to February
2013. Currently, acute aortic dissection or other urgent pathologies
are not considered as appropriate candidates for VSARR in our
department [12–14]. Preoperative factors, mortality, morbidity,
and long-term outcomes were interrogated and risk factors for
death and recurrent AI with or without aortic valve (AV)
reoperation were evaluated.
Patient characteristics are shown in Table 1. Mean age was
33.1  14.5 years and 38 (64.4%) were male. Primary diagnoses were
all AAE. The number of patients with MFS was 47 (80%). Deﬁnite
diagnosis of MFS was ﬁrst based on 1996 Ghent Nosology, and
2010 revisedGhentNosologywas applied to themore recent patients.
Note that, two patients of Loeys–Dietz syndrome were included and
counted as MFS. Only one patient (2%) was with bicuspid aortic valve
(BAV) because we do not actively perform VSARR for BAV.
Operative procedures
Table 2 shows operative details. Three (5%) cases had previous
cardiac surgeries. Cross-clamp time was 245  54 min, and it hasbeen less than 3 h since 2010. Aortic valve plasty (AVP) was added in
nine cases, most of which were just central plication.
Operative indication of ARR for AAE is basically based on the
guidelines from the Japanese Circulation Society [15], from
Table 3
In-hospital mortalities and morbidities.
David V-UT (n=59)
In-hospital mortality (%) 0 (0.0)
Homologous transfusion required (%) 17 (29)
Ventilation >72h (%) 3 (5)
ICU stay (day) 2.1 0.7
Hospital stay (day) 20.813.8
Reoperation for bleeding (%) 2 (3)
Reoperation for cardiac reason (%) 1 (2)
Perioperative myocardial infarction (%) 2 (3)
Cerebrovascular event (%) 4 (7)
Renal dysfunction (%) 3 (5)
Hemodialysis required (%) 1 (2)
Complete atrioventricular block (%) 2 (3)
Atrial ﬁbrillation (%) 5 (9)
Mediastinitis (%) 0 (0.0)
ICU: intensive care unit.
[(Fig._1)TD$FIG]
Fig. 1. Postoperative survival.
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Association (ACC/AHA), and from the Society of Thoracic Surgeons
[16,17]. In principle, we operate on aortic root greater than 50–
55 mm. In MFS, aortic root greater than 45 mm is indicated.
Especially in MFS with familial cardiovascular event or history of
aortic dissection, aortic root greater than 40 mm is also indicated.
Among these candidates for ARR, VSARRs were performed
in selected cases. Minimum requirements of VSARR in our
institution are non-urgent AAE without major morphological
changes in leaﬂets, preserved left ventricular function (left
ventricular ejection fraction greater than 40%), and acceptable
aortic annulus diameter (less than 30 mm). Today we do not
strongly recommend VSARR in patients older than 65 years
because bioprosthetic composite provides satisfactory outcomes.
Surgical technique of David V-UT
Details of David V-UT procedure have been published [11] and
brief overview of our technique is as follows. In the recent era, we
basically choose to use a collagen-impregnated woven Dacron
graft with a diameter 6 mm larger than actual annular diameter.
The diameter of graft is trimmed down proximally by 6 mm with
4-0 monoﬁlament polyester sutures at three sites. Fifteen
monoﬁlament polyester 4-0 mattress sutures with pledgets are
placed in the left ventricular outﬂow tract. Then, the aortic root is
incorporated inside the graft, and the three pleats of the proximal
edge of the graft are placed at the foot of the commissural posts to
facilitate ﬁrm suturing of the remnant native sinus wall to the
interior graft surface. The top of each commissural post is placed
inside the graft by a mattress suture, and the position is conﬁrmed
by a water test to reduce cusp prolapse. The remnant Valsalva wall
inside the graft is secured with a 5-0 polypropylene running
suture. After coronary reimplantation, the graft length is adjusted.
Then, at the middle of each sinus, longitudinal suture lines are
made from the level of commissural top toward the distal end of
the graft with running sutures, reducing the distal graft diameter
by approximately 6 mm. The schema of David V-UT has been
already published [11]. In MFS, the distal ascending aorta is
wrapped with the rest of the graft material.
Follow-up
Follow-up information was gathered from chart reviews, direct
telephone interviews, or contact with the primary care physician.
Most patients have been followed up by ourselves. Anticoagulation
with prothrombin time–international normalized ratio of 1.5–2.0
was provided until postoperative 3 months. Transthoracic
echocardiography was performed every 6–12 months.
Statistical analysis
All statistics were performed by using PASW Statistics version
18.0 for Windows (IBM SPSS, Chicago, IL, USA). All variables are
expressed as mean  standard deviation. Postoperative survival and
freedom-from-event curves were estimated by Kaplan–Meier meth-
od. Risk factors for adverse events including death or recurrent AI
greater thanmild with or without AV reoperation were assessed with
a Cox proportional-hazards model. Hazard ratio with 95% conﬁdence
interval (C.I.) and related p-value for each variable are depicted.
Statistical signiﬁcance was considered at p < 0.05.
Results
Table 3 shows in-hospital mortalities and morbidities. No in-
hospital mortality was observed. One patient needed reoperation
for pseudoaneurysm formation in the aortic root, successfullytreated with direct closure of its oriﬁce. Four patients had suffered
from cerebrovascular events, and all of which were just transient
ischemic attacks.
Postoperative survival is shown in Fig. 1. Mean follow-up
duration was 4.9  2.4 years (median 4.9 years). Estimated survival
was 94.0  3.4% at 5 years. The causes of late mortality are shown in
Table 4. Four patients died in the follow-up period and two of them
were sudden deaths. As for these two sudden deaths, one case had a
history of pacemaker implantation, but the record of which was
suggesting ventricular ﬁbrillation. The cause of death in another case
was deﬁnitely unknown. The other two cases were postpartum
subarachnoid hemorrhage, which was unpredictable, and low output
syndrome after aortic valve replacement for recurrent AI.
Fig. 2a and b demonstrates Kaplan–Meier curves for freedom
from AV reoperation and recurrent AI greater than mild. Of note,
residual AI immediately after surgery was nonexistent to trace in
47 patients (80%) and mild in 12 patients (20%). Freedom from AV
reoperation was 95.7  3.0% at 5 years, and freedom from recurrent
AI was 88.9  4.7% at 5 years. All four AI-recurrent cases are shown in
Table 5, one of which necessitated AV reoperation 3.1 years after
David V-UT.
Table 6 shows univariate Cox regression analysis for adverse
events. The deﬁnition of adverse events is AV reoperation,
recurrent AI greater than mild, or death. Preoperative AI
greater than mild and Z score (Zs) of annular diameter were
signiﬁcant risks for the adverse events (p = 0.027 and 0.045,
[(Fig._2)TD$FIG]
Fig. 2. (a) Freedom from aortic valve reoperation. (b) Freedom from recurrent aortic insufﬁciency greater than mild.
Table 4
Causes of late mortalities.
Age Sex Marfan Operation Survival (years) Causes of death
28 Male Yes David V-UT 3.6 Sudden death
24 Female Yes David V-UT 5.0 Postpartum SAH
28 Female Yes David V-UT+AVP 0.9 Sudden death (arrhythmia s/o)
58 Male No David V-UT+CABG 3.1 Low output syndrome (p-AVR)
SAH: subarachnoid hemorrhage; AVP: aortic valve plasty; CABG: coronary artery bypass grafting; AVR: aortic valve replacement.
Table 5
AI-recurrent cases.
Age Sex MFS Root Zs Annulus Zs BAV Preope. AI Operation Postope. AI Free from
AI (years)
AV reope. Free from
AV reope.
[39_TD$DIFF](years)
42 M Yes 9.3 2.8 No Moderate David V-UT+AVP None 3.4 No 7.5 (ongoing)
25 M Yes 6.0 1.4 No Severe David V-UT+AVP Mild 0.5 No 5.2 (ongoing)
58 M No 13.4 2.3 No Severe David V-UT+CABG1 Trace 3.1 Yes 3.1
17 M Yes 6.4 3.5 No None David V-UT Mild 1.7 No 1.7 (ongoing)
AI: aortic insufﬁciency; MFS: Marfan syndrome; Zs: Z score; BAV: bicuspid aortic valve; AV reope: aortic valve reoperation; AVP: aortic valve plasty; CABG: coronary
artery bypass grafting.
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2.035, respectively).
Discussion
Since VSARR was ﬁrst reported by Yacoub [2] and David [3],
there have been many modiﬁcations applied to their originalTable 6
Univariate Cox regression analyses for adverse events.
Univariate p Hazard ratio 95% C.I.
Age 0.911 1.003 0.958–1.049
Sex, male 0.431 0.526 0.106–2.606
Height 0.585 1.015 0.961–1.073
Weight 0.870 1.004 0.955–1.056
Marfan syndrome 0.841 1.178 0.237–5.848
EF<60% 0.302 0.469 0.111–1.978
Preoperative AI>mild 0.027 6.084 1.225–30.21
Postoperative AI> trace 0.983 0.983 0.198–4.885
Cross-clamp time 0.811 1.002 0.986–1.018
Root diameter 0.376 1.091 0.900–1.322
Annular diameter 0.045 1.432 1.008–2.035
C.I.: conﬁdence interval; EF: ejection fraction; Zs: Z score; AI: aortic
insufﬁciency.techniques, includingmethods by Cochran et al. [18], a ‘sinus graft’
by De Paulis and coworkers [9,19,20], the David V technique
[21,22], and its simplemodiﬁcation byMiller and Demers [8]. Main
interests were how to create pseudosinus for better cusp property,
making the technique simple, decreasing the number of suture
lines for less bleeding, and preventing annular dilatation during
decades of follow-up. Our group previously reported a simple
modiﬁcation of David V procedure [11], and the purposes of the
present study were to investigate its long-term outcome and to
clarify the risk factors for adverse eventswith this novel procedure.
As a result, David V-UT provided satisfactory outcomes from the
aspect of preventing recurrent AI, even in our Marfan-based
population (Fig. 2a and b).
The point of David V-UT is applying three longitudinal size-
reduction running sutures to the distal end of the graft, permitting
natural ﬂow beyond the sinotubular junction, in contrast to the
localized sutures only at the sinotubular junction of the original
David V technique [6]. These simple running sutures enabled us to
create pseudosinus such as native Valsalva using just one graft.
Follow-up three-dimensional computed tomography a few years
after the surgery demonstrated preservation of trilobed aortic
sinus [11]. Miller and Demers reported their original modiﬁcation
of David V [8], whichwas using two separated grafts with different
M. Ando et al. / Journal of Cardiology 67 (2016) 86–9190size. Our technique uses only one graft, which may be more cost-
effective, and it necessitates fewer anastomoses than their
technique and the risk of postoperative bleeding might be low.
Besides, cross-section of native Valsalva is not completely circular,
but trilobed. Our technique may have a beneﬁt of mimicking this
trilobed shape of native Valsalva and this might possibly affect
cusp property after decades of follow-up. De Paulis et al. reported
outcome of Valsalva graft [9,20,23]. The advantages of David V-UT
over their technique are, ﬁrst, similar to Miller’s modiﬁcation, the
distal end of graft has a large diameter, so valve suturing inside
the graft can be easily and safely done. Second, pseudosinuses are
created after the heights of the commissural posts are determined,
so that their size can be freely adjusted. In contrast to other
modiﬁcations, David V-UT is not a ‘‘ready-made’’ procedure, but a
‘‘custom-made’’ one, in which we are able to tailor subtle
differences in each patient. We always keep in mind the locations
and heights of the three commissures before trimming of the
sinus tissue and attach them in natural positions to avoid excess
mechanical stress on the leaﬂet. Then, longitudinal sutures were
added according to the sinus sizes. We believe that this ﬂexibility
of commissural height set-up is extremely important in VSARR,
even though it is not easy to quantify its actual beneﬁt, because
the most common causes of late failure are cusp prolapse and
commissural dehiscence.
The target population was characterized by MFS, correspond-
ing to 80% (Table 1). This is partly because our department is
managing an MFS-specialized clinic. It is also worth pointing out
that most of the patients were young with MFS without
atherosclerotic changes and such patients underwent surgery
during close observation for years. Therefore, they might have
undergone surgery relatively earlier than a non-MFS population.
For fragile aortic tissue in MFS, large diameter gap in anastomosis
is not favorable. Size-reduction sutures of David V-UT would
especially beneﬁt our MFS-based population.
Table 2 shows operative details. AVP were added in nine
patients. In these nine AVPs, eight caseswere just central plications
after water regurgitation test. In our current policy, if we estimate
thatwe need further valve plastic procedures, we do not hesitate to
perform valve-replacing ARR for future cusp property. In fact, since
2004 when we initially started David V-UT, there were 95 candi-
dates of ARR for non-urgent AAE, andwe actually performed David
V-UT in 59 patients (62.1%). Looking back into the annual report of
2012 by the Japanese Association for Thoracic Surgery [24], among
the ARRs performed for non-dissection disease in Japan, VSARR
was only performed in less than half cases. The data suggest, as a
general trend, VSARR in Japan is not a gold standard for the
treatment of non-urgent AAE.
Cross-clamp time was relatively longer than in other studies
[22,25], mainly because we spend time in careful determination of
commissural-post height until we get perfect leaﬂet coaptation.
The average ischemic time in the recent few yearswas less than 3 h
possibly due to learning-curve process. Even though no cases
suffered from myocardial damage for longer ischemic time, we
need to continue to proceedwith great effort. In-hospital mortality
and morbidity rates were satisfactory (Table 3). Even in selected
cases, it should be noted that our operative mortality was zero in
the MFS-based population. We are actively utilizing autologous
blood transfusion and the rate of homologous blood transfusion
was 29% (17 out of 59 cases). Hospital stay was 20.8  13.8 days
and may seem longer, mainly because our primary health-care
system is different from western countries.
David V-UT provided 5-year survival of 94.0  3.4% (Fig. 1). The
group also provided satisfactory outcomes in freedom from AV
reoperation and recurrent AI, whichwere 95.7  3.0% and 88.9  4.7%
at 5 years respectively (Fig. 2a and b). Kvitting et al. reported
outcomes of their own David V modiﬁcation, including 233 patientsfrom 1993 to 2009 with follow-up interval of 4.7  3.7 years.
Although their population consisted of 40% MFS and 27% BAV,
survival at 5 and 10 years were 98.7  0.7% and 93.5  5.1%,
respectively. Freedom from reoperation on the aortic root was
92.2  3.6% at 10 years [25]. David et al. reported 296 VSARR patients
(36% MFS and 11% BAV) from 1989 to 2010 with mean follow-up of
6.9  4.5 years, the result of which was tremendous. The survivals at
5, 10, and 15 years were 95.1  3.5%, 93.1  4.4%, and 76.5  18%,
respectively. Only three patients required AV reoperation and
freedoms from AV reoperation at 5, 10, and 15 years were
99.7  2.0%, 97.8  5.3%, and 97.8  5.3%, respectively [22]. De Paulis
and colleagues reported the results of 278 patients (15%MFS and 11%
BAV) who had undergone David reimplantation using Valsalva graft
[9]. Mean follow-up was 4.3  2.3 years, and actuarial survival was
95.2% at 10 years. Freedoms from AV reoperation and residual AI not
needing reoperation were 91% and 88% at 10 years. Even though we
ﬁrst started VSARR in 1998 and David V-UT in 2004, our outcomes are
following these leading centers.
We observed four cases of late mortalities (Table 4). Two
sudden deaths were seen and both of them were in patients with
MFS. Autopsy was performed to reveal no dissection. The exact
causes of these sudden deaths are still unknown, but arrhythmic
death is highly suspected [26]. Hoffmann et al. followedup77MFS
patients with median follow-up of 872.0 days (752.5–990.5).
Seven (9.1%) patients exhibited composite endpoints of sudden
cardiac deaths, sustained ventricular tachycardia, ventricular
ﬁbrillation, or arrhythmogenic syncope [27]. Two patients (2.1%)
died due to sudden cardiac death, which was a sevenfold increase
comparedwith the general population. Autopsieswereperformed
in both cases, revealing an intact aorta/aortic root and normal
coronary vessels. In our 47 MFS patients, two patients (4%) died
due to sudden death during 5-year follow-up,which is close to the
natural history of MFS in Hoffmann’s report. These data may
suggest the necessity of regular follow-up for MFS after VSARR
withHolter electrocardiogramorothermonitoringmethods. Even
if patients are asymptomatic, medication or implantable cardiac
deﬁbrillator should be considered to prevent these sudden
rhythmic deaths.
Preoperative AI greater than mild and Zs of annular diameter
were signiﬁcant risk factors for adverse events in univariate
analysis (Table 6). In previous reports, preoperative AI is singled
out as a risk factor for adverse events [1,25,28], but Zs of annular
diameter is rarely mentioned. Our data showed that there was no
correlation between Zs of aortic annulus and aortic root
(R2 = 0.32), and only Zs of annular diameter showed statistical
signiﬁcance as a risk factor. This implies, even if a patient has
large aortic root that VSARR can be rather safely indicated if
the size of annulus is maintained, and vice versa. In our study,
MFS was not an independent risk factor for adverse events.
Shrestha et al. reported outcomes of David I VSARR, including
126 patients (20.6% of MFS and 4.0% of BAV) from 1993 to
2000 with mean follow-up of 10  2 years. In their study, MFS was
a possible predictor of reoperation and overall mortality [28]. Leon-
tyev et al. also reported MFS was a risk factor for recurrent AI [29].
On the contrary, Kvitting et al. reported MFS was not a signiﬁcant
risk for adverse events [25], compatible to our data. Both Kvitting’s
and our patients were based largely on MFS populations, which
were 40% and 80% respectively. Considering a current trend that
recommends VSARR in MFS or other connective tissue disorders
[4,5], we believe VSARR can be safely performed even in MFS in
experienced institutions.
Study limitations
The present study has several limitations. First, the number of
patients included in the present study is limited, and its population
M. Ando et al. / Journal of Cardiology 67 (2016) 86–91 91is rather selected, which is characterized by young MFS with
normal valvemorphology. This is mainly because we have anMFS-
specialized clinic referring most of VSARR candidates and baseline
candidacy for ARR has a biased distribution to Marfan patients.
However of note, it does not necessarily mean that we are
speciﬁcally picking up Marfan cases among the whole population.
Second, we did not actively perform VSARR in BAV patients. This is
because the beneﬁt of routine VSARR in BAV is yet to be clearly
addressed in the current guidelines, and our goal has been
prudently providing secure long-term outcomes in each patient.
Third, the number of adverse events in Cox analysis was 8 out of
59. Because of this small number of events, we abandoned
multivariate analysis. Despite these limitations, the present study
is unique andworthwhile in that it revealed satisfactory long-term
outcomes and risk factors for adverse events after David V-UT,
especially in Marfan-characterized population.
Conclusion
Even in a Marfan-characterized population, David V-UT
provided satisfactory long-term outcomes, comparable to other
modiﬁcations of VSARR. It is simple but can freely reproduce
trilobed sinus similar to a native one with one straight graft. The
other beneﬁt of David V-UT is, in contrast to ready-made Valsalva
graft technique, that it can provide more ﬂexibility in commissural
height adjustment. Further reﬁnement and workup are needed to
validate this technique, especially in patients with greater AI or
larger annulus.
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